Interferon beta remains a cornerstone disease-modifying therapy in relapsing forms of multiple sclerosis. However, its utility is compromised by immunogenicity, whereby patients develop anti-drug ...
Elevated interferon alfa levels mark a subgroup of Sjögren disease, revealing immune changes years before diagnosis, and mice studies mirror these findings.